Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Biosciences Q4 Revenues Up 15 Percent

NEW YORK (GenomeWeb) – Pressure Biosciences reported on Wednesday that its total fourth quarter revenues in 2016 rose 15 percent, as an increase in products and services revenues was softened by a decrease in grant revenues.

For the three months ended Dec. 31, 2016 the lab instruments and consumables manufacturer reported revenues of $419,711, up from $364,119 a year earlier.

Products and services revenues rose 55 percent to $365,262 from $235,600 in the same quarter of 2015. Sales of consumables rose 70 percent year over year to $50,054 from $29,521. Grant revenues for Q4 fell 58 percent year over year to $54,449 from $128,519 in Q4 2015.

The company reported a net income of $3.2 million, or $.03 per share, compared to a net loss of $4.0 million, or $.19 per share, a year earlier.

For the recently completed quarter, Pressure Bio used 104.4 million shares to calculate its profit on a per-share basis, compared to 21.5 million shares used to calculate its per-share loss a year ago.

R&D costs for the quarter rose 14 percent to $257,996 from $226,396 in Q4 2015, while SG&A expenses rose 20 percent to $1.2 million from $1.0 million.

For full-year 2016, the firm reported that total revenues rose 10 percent to $2.0 million from $1.8 million in 2015.

Products and services revenues rose 27 percent to $1.8 million from $1.4 million last year. Sales of consumables rose 37 percent to $199,873 from $146,408. Grant revenues for 2016 fell 53 percent to $181,738 from $387,700.

"Our accomplishments over the past year have set the stage for what we believe will be a very successful 2017," Pressure President and CEO Richard Schumacher said in a statement. "These accomplishments have let us enter the new year with a stronger balance sheet; a broader product offering; an award-winning, next-generation instrument; important additions to our hardworking and talented staff; a larger customer base; and an expanded and enhanced sales and marketing capability."

The company's net loss for the year narrowed to $2.7 million, or $.10 per share, from $7.4 million, or $.36 per share, a year ago.

R&D costs for the year rose 9 percent to $1.2 million from $1.1 million in 2015, while SG&A expenses rose 3 percent to $3.7 million from $3.6 million.

Pressure Bio ended the year with $138,363 in cash and cash equivalents.

For 2017, Schumacher said the company's goals include "an up-list to the Nasdaq stock market in Q2 2017; measurable progress in completing and implementing a sound roadmap toward financial self-sufficiency and future growth and prosperity; continuation of the current expansion of our sales and marketing capabilities, and our reach into new countries, investigators, and fields-of-use; and a focus on sales."

Pressure Bio's shares rose nearly 6 percent to $.27 in afternoon trading on the OTC market.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.